Hims & Hers Health, Inc. (NYSE:HIMS) Receives $37.23 Consensus Price Target from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned an average rating of “Hold” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $37.23.

A number of research analysts have commented on HIMS shares. Piper Sandler raised their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Bank of America restated an “underperform” rating and issued a $21.00 price target on shares of Hims & Hers Health in a report on Thursday. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Citigroup restated a “sell” rating and issued a $27.00 price target on shares of Hims & Hers Health in a report on Thursday.

Hims & Hers Health Price Performance

HIMS stock opened at $36.01 on Friday. The company has a market capitalization of $8.00 billion, a PE ratio of 81.85 and a beta of 1.37. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98. The firm’s 50-day moving average is $37.45 and its 200 day moving average is $27.31.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $4,659,976.07. The trade was a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,062,011 shares of company stock worth $36,892,724. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the company. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at about $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.